查看文章

The current COVID-19 pandemic is forcing caregivers to adapt their clinical practice, especially for the management of life-threatening conditions such as urological malignancies. During this health care crisis it is important to weigh the risk of contamination related to breaking lockdown for treatment delivery against the risk of jeopardizing cancer prognosis by delaying any form of treatment. This consideration is of utmost relevance for patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who require repeat visits to hospital for intravesical instillations of bacillus Calmette-Guérin (BCG) to decrease the risk of recurrence and progression after transurethral resection of the bladder (TURB). The median age at initial diagnosis in this patient population is> 70 yr [1] and it has recently been reported that almost 30% of patients older than 65 yr may develop acute respiratory distress syndrome after contracting …